Neumora Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 3, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 3, 2025
NMRA$0.49-3.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except par values)
| December 31,2024 | December 31,2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $142,148 | $374,038 |
| Restricted cash | 1,213 | — |
| Short-term marketable securities | 165,430 | 79,944 |
| Prepaid expenses and other current assets | 5,264 | 24,297 |
| Total current assets | 314,055 | 478,279 |
| Long-term marketable securities | — | 9,845 |
| Property and equipment, net | 1,140 | 1,790 |
| Operating lease right-of-use assets | 1,777 | 5,068 |
| Restricted cash | — | 1,213 |
| Total assets | $316,972 | $496,195 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $3,307 | $337 |
| Accrued liabilities | 24,593 | 21,257 |
| Early exercise liability, current portion | 133 | 139 |
| Operating lease liabilities, current portion | 1,853 | 3,378 |
| Total current liabilities | 29,886 | 25,111 |
| Operating lease liabilities, net of current portion | — | 1,853 |
| Early exercise liability, net of current portion | 22 | 155 |
| Total liabilities | 29,908 | 27,119 |
| Commitments and contingencies (Note 7) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 50,000 shares authorized as of December 31, 2024 and December 31, 2023; no shares issued and outstanding as of December 31, 2024 and December 31, 2023. | — | — |
| Common stock, $0.0001 par value; 700,000 shares authorized as of December 31, 2024 and December 31, 2023; 161,710 and 158,832 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively. | 16 | 16 |
| Additional paid-in capital | 1,234,207 | 1,172,570 |
| Accumulated other comprehensive (gain) loss | 62 | (76) |
| Accumulated deficit | (947,221) | (703,434) |
| Total stockholders’ equity | 287,064 | 469,076 |
| Total liabilities and stockholders’ equity | $316,972 | $496,195 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.